Table 3 Temporal trends of patient characteristics’ in patients with advanced CKD (G3b-G5)
| Â | Time period | |||
|---|---|---|---|---|
T1 2006–2010 (n = 407) | T2 2011–2015 (n = 313) | T3 2016–2019 (n = 298) | Significance | |
Age (years ± SD) | 74.5 ± 10 | 76.8 ± 12 | 76.6 ± 11 | 0.012 |
Women (%) | 44.7 | 53.2 | 42.6 | 0.72 |
Body mass index (BMI) (kg/m2 ± SD) | 27.5 ± 5 | 27.1 ± 5 | 26.9 ± 5 | 0.09 |
Diabetes (%) | 32.0 | 29.0 | 27.4 | 0.15 |
Current smokers (%) | 19.2 | 16.2 | 11.8 |  < 0.01 |
Arterial hypertension (%) | 72.6 | 73.6 | 70.0 | 0.46 |
Treatment strategy | ||||
 Primary PCI (%) | 75.8 | 88.8 | 90.3 | < 0.01 |
 Urgent/early elect. CABG (%) | 10.4 | 6.1 | 5.1 | < 0.01 |
 Conservative (%) | 13.8 | 5.1 | 4.7 | < 0.01 |
Coronary vessels diseased | ||||
 1 (%) | 19.3 | 26.7 | 19.5 | 0.79 |
 2 (%) | 32.7 | 29.1 | 26.7 | 0.09 |
 3 (%) | 48.1 | 44.1 | 53.8 | 0.2 |
Cardiogenic shock (%) | 29.9 | 28.8 | 34.6 | 0.24 |
TIMI 0/1 flow after PCI (%) | 11.1 | 10.8 | 9.8 | 0.56 |
Peak CK > 2000 U/l (%) | 26.6 | 30.1 | 30.3 | 0.29 |
Contrast media used (ml ± SD) | 132 ± 62 | 153 ± 76 | 152 ± 73 | < 0.01 |
Contrast media > 150 ml (%) | 27.7 | 43.0 | 41.6 | < 0.01 |
Stent type in PCI cohort | ||||
 Bare metal stent (%) | 88.3 | 42.8 | 0.3 | < 0.01 |
 Drug eluting stent (%) | 1.3 | 46.4 | 90.7 | < 0.01 |
 No stent (POBA) (%) | 10.4 | 10.7 | 8.9 | 0.52 |
No. of stents impl. (n ± SD) | 1.3 ± 0.6 | 1.5 ± 0.8 | 1.8 ± 1.0 |  < 0.01 |
Medication at discharge | ||||
 ASS (%) | 91.9 | 89.1 | 86.5 | < 0.02 |
 Clopidogrel (%) | 83.0 | 48.3 | 28.2 | < 0.01 |
 Ticagrelor or prasugrel(%) | 1.7 | 44.1 | 59.6 | < 0.01 |
 Triple therapy (%) | 16.1 | 12.1 | 8.8 | < 0.01 |
 DAPT-duration (months ± SD) | 2.5 ± 3 | 7.9 ± 5 | 10.9 ± 4 | < 0.01 |
 DAPT-duration > 6 months (%) | 8.9 | 58.2 | 89.2 | < 0.01 |
 Statin (%) | 71.4 | 66.1 | 65.6 | 0.11 |
 ACE-inhibitor/ATR (%) | 55.6 | 56.7 | 55.1 | 0.88 |
 Betablocker (%) | 70.4 | 61.9 | 59.6 | < 0.01 |